Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Suzhou MedicalSystem Technology Co., Ltd. (603990.SS)
Suzhou, CN
Suzhou MedicalSystem Technology Co., Ltd., established in Suzhou, China, in 2005, is a company dedicated to developing and implementing advanced clinical information technology and digital hospital management solutions throughout China. Their product portfolio primarily features the "DoCare" suite of systems: The DoCare anesthesia clinical information system is tailored for the perioperative environment, offering an integrated platform that streamlines, digitalizes, automates, and intelligently manages clinical workflows during surgical procedures. The DoCare intensive auxiliary diagnosis clinical information system focuses on extracting and scientifically analyzing treatment data from ICU patients. It integrates diverse medical information, including treatment details, inspection results, nursing records, and doctor's orders, to support diagnosis and decision-making. The DoCare operative medical behavior management system provides intelligent oversight for operating room resources and staff activities. The DoCare emergency clinical information system offers comprehensive management for emergency care services. This spans the entire patient journey, from pre-hospital first aid and initial triage to active rescue, emergency observation, specialized emergency operating rooms and ICUs, and final patient outcomes. The DoCare pre-hospital first aid clinical information system creates a unified digital service platform connecting emergency command centers, medical personnel (doctors, nurses, visiting staff), and patients for pre-hospital care. Beyond these core offerings, the company also provides specialized "smart" solutions for operating theaters (OT), intensive care units (ICUs), and emergency departments. Additionally, their smart specialty solutions include systems for laminar airflow rooms, clinical pathways, mobile nursing information, and central sterile supply department (CSSD) management.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.14% | +15.47% | +24.08% | +31.57% | +25.11% | +29.40% | +31.22% | +28.98% | -8.14% | +293.39% | +293.39% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Healthcare Information Services: +14.2%-35.4% Q1'26: -2.6% (vs Q1'25)
-
EPS growth Medical - Healthcare Information Services: +43.1%+114.1% ★ Q1'26: -84.3% (vs Q1'25)
-
FCF margin FCF growth · Medical - Healthcare Information Services: +49.2%+2.4% Q1'26: -25.1% (vs Q1'25)
-
EBIT margin Medical - Healthcare Information Services: +8.8%+5.6% Q1'26: +6.7% (vs Q1'25)
-
ROIC Medical - Healthcare Information Services: +5.2%+1.9% Q1'26: +2.7% (vs Q1'25)
-
Share dilution Medical - Healthcare Information Services: -0.1%-0.4% ★ Q1'26: +3.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Healthcare Information Services: -0.74×5.65× Q1'26: 15.80× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
333.12M
est: 326.00M (+2.2%)
|
308.08M
est: 355.00M (-13.2%)
|
353.85M
est: 500.00M (-29.2%)
|
305.51M
est: 661.00M (-53.8%)
|
618.14M
est: 620.00M (-0.3%)
|
464.07M
est: 3.67B (-87.4%)
|
299.60M
est: 343.00M (-12.7%)
|
394.00M
394.00M – 394.00M
+14.9% YoY
|
479.00M
479.00M – 479.00M
+21.6% YoY
|
549.00M
549.00M – 549.00M
+14.6% YoY
|
| EBITDA |
73.33M
est: 9.82M (+646.9%)
|
70.10M
est: 10.69M (+555.6%)
|
71.78M
est: 15.06M (+376.7%)
|
61.79M
est: 19.91M (+210.4%)
|
-187.07M
est: 18.67M (-1,101.8%)
|
-124.96M
est: -2.75M (-4,449.9%)
|
48.85M
est: -256.5K (+19,142.2%)
|
-294.7K
-294.7K – -294.7K
-14.9% YoY
|
-358.3K
-358.3K – -358.3K
-21.6% YoY
|
-410.6K
-410.6K – -410.6K
-14.6% YoY
|
| EBIT |
59.38M
est: -15.80M (+475.9%)
|
55.47M
est: -17.20M (+422.5%)
|
58.25M
est: -24.23M (+340.4%)
|
47.67M
est: -32.03M (+248.8%)
|
-213.22M
est: -30.04M (-609.7%)
|
-181.51M
est: -263.84M (+31.2%)
|
16.82M
est: -24.65M (+168.2%)
|
-28.31M
-28.31M – -28.31M
-14.9% YoY
|
-34.42M
-34.42M – -34.42M
-21.6% YoY
|
-39.45M
-39.45M – -39.45M
-14.6% YoY
|
| Net Income |
46.89M
est: 82.27M (-43.0%)
|
35.44M
est: 57.52M (-38.4%)
|
41.95M
est: 86.28M (-51.4%)
|
33.56M
est: 118.63M (-71.7%)
|
-269.42M
est: -182.27M (-47.8%)
|
-279.47M
est: 151.34M (-284.7%)
|
39.16M
est: 60.54M (-35.3%)
|
72.64M
72.64M – 72.64M
+20.0% YoY
|
99.88M
99.88M – 99.88M
+37.5% YoY
|
121.07M
121.07M – 121.07M
+21.2% YoY
|
| SGA |
126.02M
est: 73.05M (+72.5%)
|
129.68M
est: 79.55M (+63.0%)
|
147.19M
est: 112.04M (+31.4%)
|
122.93M
est: 148.11M (-17.0%)
|
271.50M
est: 138.92M (+95.4%)
|
224.50M
est: 1.39B (-83.9%)
|
46.57M
est: 130.12M (-64.2%)
|
149.47M
149.47M – 149.47M
+14.9% YoY
|
181.71M
181.71M – 181.71M
+21.6% YoY
|
208.27M
208.27M – 208.27M
+14.6% YoY
|
| EPS |
0.19
est: 0.27 (-29.8%)
|
0.14
est: 0.19 (-26.1%)
|
0.15
est: 0.28 (-47.2%)
|
0.12
est: 0.39 (-69.3%)
|
-0.88
est: -0.60 (-46.7%)
|
-0.92
est: 0.50 (-284.0%)
|
0.13
est: 0.20 (-35.0%)
|
0.24
0.24 – 0.24
+20.0% YoY
|
0.33
0.33 – 0.33
+37.5% YoY
|
0.40
0.40 – 0.40
+21.2% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 1/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 2/5 | 3/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 3/5 | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Di Wu | Deputy General Manager | — | male |
| Fengying Liu | Accounting Supervisor | — | — |
| Hao Mei | Financial Director | — | male |
| Meng Hao Li | Deputy GM & Secretary of the Board of Directors | — | male |
| Weng Kang | Vice Chairman & GM | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603990.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
